Transforming biotech to tech-bio

Small Molecule andPeptide DiscoveryAI Diagnostics ForLongevityDecentralizedData AcquisitionGlobalPartnerships

Two validated AI platforms for rapidly identifying small molecules and peptides — deployed through clinical, academic, commercial and decentralized partners to scale revenue and impact patients.

Contact Us
Latest

Collaboration and revenue share agreement signed with Hadassah Medical Organization and Ariel University

Read more →

Our mission

Getting to the right discovery faster, and validating it through global partnerships.

Revolutionizing Biotech through AI Protocols

Established in 2023, DiaGen AI leverages proprietary AI protocols to accelerate the shift from Biotech to Tech-Bio, dramatically de-risking and optimizing traditional laboratory discovery in therapeutics and diagnostics.

Fueling Scalability through Global Partnerships

Our global partner network, independent laboratories, and proprietary data pipelines power an AI-first strategy that drives near-term revenue and maximizes patient impact. Through scalable global operations, DiaGen retains or co-owns the high-value intellectual property generated.

Pioneering Longevity-Focused Discoveries

Led by a world-class team of experts, DiaGen AI specializes in the novel discovery of peptides, biomarkers, and diagnostics, with a primary focus on extending human longevity.

See who we work with →
2Validated AI platforms
7Active partnerships
4Regions: NA / EU / MENA / APAC
6.75MMolecules in the foundation model

The engine

Two platforms, two modalities, both validated at the bench.

BLACKCOMB explores adjacent chemical space around lead and patent compounds to produce novel, patentable analogs. CYPRESS finds the single most effective binder from billions of peptide candidates. Each has a result that came back from an outside lab, not from a benchmark we wrote ourselves.

How the platforms work →

Small molecule platform

BLACKCOMB Protocol

Molecule optimization and acceleration.

  • Atomic-resolution foundation model trained on 6.75M molecules
  • Flow-network generative architecture, physics-informed
  • Explores adjacent chemical space around lead and patent compounds to produce novel, patentable analogs
  • Objective setup across MW, LogP, QED and custom targets, with similarity-to-seed control
  • 2D and 3D structures, docking poses and interaction analysis in a single view
Validated externally

KRAS-G12D degradation confirmed in cells by the Structural Genomics Consortium.

Peptide platform

CYPRESS Protocol

Peptide research efficacy and precision.

  • Identifies the most effective binder from billions of candidates
  • End-to-end in silico pipeline: hotspot ID → backbone → sequence → MD validation
  • Conditional sequence design using GFlowNets, protein LLMs and discrete diffusion
  • Materially lower compute demand than conventional screening
  • Bespoke binders for therapeutic and biosensor targets alike
Validated externally

A designed 30-mer holds a stable complex with C-reactive protein across a 100-ns MD simulation.

Pipeline

Programs advancing with named partners.

Assets move from generative design into partner wet labs. The KRAS oncology catalog is the furthest along and is available for partnering today, with IP retained in full by DiaGen.

View the full pipeline →
AreaProgramPartner
DesignWet-labPre-clinicalPartnering
Oncology
DGEN1-5 KRAS catalogPancreatic & colorectal cancer
UNC — Structural Genomics Consortium
Peptide therapeutics
Three co-development projectsToward commercialization
Hadassah — Hadasit / Ariel University
Radiopharma
Radiopharma co-development
Hadassah — Hadasit / Ariel University
Longevity diagnostics
CRP biosensor · L.I.V.E.Continuous biochemical monitoring
University lab — under NDA
Discovery tooling
Multi-objective hit-picking toolNovelty, affinity, target specificity
MetaNova Labs — Bittensor SN68
Small molecule Peptide Scope being defined

The latest from DiaGen

Announced milestones.

Full releases are available at diagen.ai/news and via EIN Presswire.

Collaboration and revenue share agreement with Hadassah Medical Organization and Ariel University

Read more →

Life sciences and AI expert Aditya Tallapragada appointed to the advisory board

Read more →

Study published on biomarker integration and biosensor technologies in biological aging

Read more →

Tech-Bio Partnering: Tools and Deployment

For platform access, catalog partnering or co-development enquiries.

IR@diagen.ai